Catalyst Pharma Files 8-K, Confirms NASDAQ Listing
Ticker: CPRX · Form: 8-K · Filed: Jan 9, 2024 · CIK: 1369568
| Field | Detail |
|---|---|
| Company | Catalyst Pharmaceuticals, Inc. (CPRX) |
| Form Type | 8-K |
| Filed Date | Jan 9, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $15.00 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: compliance, regulatory-filing, corporate-governance
TL;DR
**Catalyst Pharma filed a routine 8-K, confirming its NASDAQ listing and standard compliance.**
AI Summary
Catalyst Pharmaceuticals, Inc. filed an 8-K on January 9, 2024, to report an "Other Event" and "Financial Statements and Exhibits." This filing primarily serves to update the public record regarding the company's current status and confirms its common stock, with a par value of $0.001 per share, is registered on the NASDAQ Capital Market. For investors, this filing is a routine update, indicating no immediate major operational or financial changes, but it reaffirms the company's compliance with SEC reporting requirements and its continued listing on a major exchange.
Why It Matters
This filing confirms Catalyst Pharmaceuticals' ongoing compliance with SEC regulations and its continued listing on the NASDAQ Capital Market, which is crucial for stock liquidity and investor confidence.
Risk Assessment
Risk Level: low — This 8-K filing is a standard procedural update and does not introduce new financial or operational risks.
Analyst Insight
A smart investor would view this as a routine compliance filing, indicating business as usual, and would look for more substantive news for investment decisions.
Key Numbers
- $0.001 — Par Value per Share (the stated par value of Catalyst Pharmaceuticals' common stock)
Key Players & Entities
- CATALYST PHARMACEUTICALS, INC. (company) — the registrant filing the 8-K
- NASDAQ Capital Market (company) — the exchange where Catalyst Pharmaceuticals' common stock is registered
- $0.001 (dollar_amount) — the par value per share of common stock
- January 9, 2024 (date) — the date of the earliest event reported in the 8-K
Forward-Looking Statements
- Catalyst Pharmaceuticals will continue to maintain its listing on the NASDAQ Capital Market. (CATALYST PHARMACEUTICALS, INC.) — high confidence, target: 2025-01-09
FAQ
What is the primary purpose of this 8-K filing by Catalyst Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing, dated January 9, 2024, is to report "Other Events" and "Financial Statements and Exhibits," serving as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
On which stock exchange is Catalyst Pharmaceuticals, Inc.'s common stock registered?
Catalyst Pharmaceuticals, Inc.'s Common Stock, with a par value of $0.001 per share, is registered on the NASDAQ Capital Market.
What is the par value of Catalyst Pharmaceuticals, Inc.'s common stock?
The par value of Catalyst Pharmaceuticals, Inc.'s common stock is $0.001 per share.
What is the earliest event reported date in this 8-K filing?
The earliest event reported date in this 8-K filing is January 9, 2024.
What is the business address of Catalyst Pharmaceuticals, Inc. as stated in the filing?
The business address of Catalyst Pharmaceuticals, Inc. is 355 Alhambra Circle, Suite 801, Coral Gables, Florida, 33134.
Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 10.3 · Accepted 2024-01-09 17:15:01
Key Financial Figures
- $0.001 — Ticker Symbol Common Stock, par value $0.001 per share NASDAQ Capital Market CPR
- $15.00 — ts common stock at an offering price of $15.00 per share. The press release is attache
Filing Documents
- d702064d8k.htm (8-K) — 24KB
- d702064dex991.htm (EX-99.1) — 10KB
- g702064g0110023741569.jpg (GRAPHIC) — 1KB
- g702064g0110023741982.jpg (GRAPHIC) — 4KB
- 0001193125-24-005292.txt ( ) — 164KB
- cprx-20240109.xsd (EX-101.SCH) — 3KB
- cprx-20240109_lab.xml (EX-101.LAB) — 18KB
- cprx-20240109_pre.xml (EX-101.PRE) — 11KB
- d702064d8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events On January 9, 2024, the Company issued a press release reporting the closing of its previously announced public offering of 10,000,000 shares of its common stock at an offering price of $15.00 per share. The press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press release issued by the Company on January 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Catalyst Pharmaceuticals, Inc. By: /s/ Michael W. Kalb Michael W. Kalb Executive Vice President and CFO Dated: January 9, 2024 3